AVITA Medical (RCEL) Canaccord Genuity's 46th Annual Growth Conference summary

Business performance and growth trajectory

• Sequential revenue growth reported over recent quarters, with revenues rising from $17.6M to $21.7M.

• Guidance raised to $86M–$89M for the year, reflecting confidence in continued growth.

• Cash flow breakeven expected in Q4, with consistent high margins and stable operating expenses.

• Cost-out initiatives completed, enabling growth without increasing OPEX or sales headcount for at least 18 months.

• Stock price has doubled since the CEO's tenure began, attributed to operational improvements and predictability.

Product portfolio and market strategy

• Three synergistic products (RECELL, Cohealyx, PermeaDerm) target acute wound care in hospitals, focusing on burn and trauma centers.

• RECELL portfolio expanded with automated and mini versions to address a broader range of wound sizes.

• Only 15% penetration in core burn centers, with significant opportunity in trauma and smaller wounds.

• Sales reps efficiently cover accounts, leveraging relationships to cross-sell products within the same procedures.

• About 25 hospitals currently use all three products, demonstrating portfolio adoption.

Clinical and economic value

• RECELL reduces patient length of stay by 36% compared to traditional skin grafts.

• Cohealyx offers faster wound bed readiness (as little as 5–13 days vs. 33 days for competitors), reducing hospital time and risk.

• PermeaDerm competes with Allograft by being less expensive, transparent, and easier to handle and store.

• Real-world and post-market clinical studies support efficacy, cost savings, and workflow improvements.

• Data-driven approach underpins both clinical adoption and economic decision-making for hospitals.